Ken Griffin Cel Sci Corp Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$1.11 - $1.85 $37,740 - $62,900	-34,000 Reduced 67.19%	16,600 $19,000
Q1 2024 May 15, 2024	SELL	$1.63 - $3.08 $512,145 - $967,736	-314,200 Reduced 86.13%	50,600 $96,000
Q4 2023 Feb 14, 2024	BUY	$1.07 - $3.07 $41,195 - $118,195	38,500 Added 11.8%	364,800 $992,000
Q3 2023 Nov 14, 2023	SELL	$1.17 - $2.86 $24,336 - $59,488	-20,800 Reduced 5.99%	326,300 $407,000
Q2 2023 Aug 14, 2023	SELL	$2.11 - $2.83 $95,372 - $127,916	-45,200 Reduced 11.52%	347,100 $836,000
Q1 2023 May 15, 2023	SELL	$2.17 - $3.13 $344,162 - $496,418	-158,600 Reduced 28.79%	392,300 $910,000
Q4 2022 Feb 14, 2023	BUY	$1.99 - $3.52 $73,431 - $129,888	36,900 Added 7.18%	550,900 $1.29 Million
Q3 2022 Nov 14, 2022	BUY	$3.09 - $5.23 $43,878 - $74,266	14,200 Added 2.84%	514,000 $1.59 Million

6.16M

16.6K

148K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $48.6M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.